Andrew R. Boll
2014
In 2014, Andrew R. Boll earned a total compensation of $300.6K as Chief Financial Officer at Imprimis Pharmaceuticals, a 54% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $95,000 |
|---|---|
| Option Awards | $45,514 |
| Salary | $154,125 |
| Other | $5,991 |
| Total | $300,630 |
Boll received $154.1K in salary, accounting for 51% of the total pay in 2014.
Boll also received $95K in non-equity incentive plan, $45.5K in option awards and $6K in other compensation.
Rankings
In 2014, Andrew R. Boll's compensation ranked 11,717th out of 13,032 executives tracked by ExecPay. In other words, Boll earned more than 10.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,717 out of 13,032 | 10th |
Division Manufacturing | 4,485 out of 4,966 | 10th |
Major group Chemicals And Allied Products | 1,545 out of 1,686 | 8th |
Industry group Drugs | 1,249 out of 1,365 | 9th |
Industry Pharmaceutical Preparations | 959 out of 1,043 | 8th |
Source: SEC filing on April 10, 2015.
Boll's colleagues
We found one more compensation record of an executive who worked with Andrew R. Boll at Imprimis Pharmaceuticals in 2014.
2014
Mark Baum
Imprimis Pharmaceuticals
Chief Executive Officer
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019